The United States (US) is one of the biggest and most fast-growing biotech markets globally and Cellomatics is looking to further expand its client base here, following its recent export achievements.
Cellomatics has identified a huge potential within the US market yet to be tapped and the company is eager to further its US expansion. The US is one of the most challenging markets to access for UK-based companies due to various factors including the geography, competitive landscape, cultural differences, pricing sensitivity and difficulty in adoption of uniform marketing strategies across all states.
In order to support Cellomatics’ US expansion, the team has welcomed Dr Jyoti Mundra to the company to lead its business development efforts. In her role, Jyoti will help accelerate the growth of Cellomatics while enhancing Cellomatics presence and business in the Americas.
Jyoti is based in New Jersey, US and brings over 15 years of experience working in a business development role at large US-based CROs where she was responsible for leading, driving growth and transforming both small and public companies in the preclinical, clinical and biomarker space.
With a PhD in Biological Sciences and postdoctoral training, she has the right blend of technical and commercial skill sets which align perfectly with Cellomatics’ requirements as a specialist preclinical biology-focused CRO.
In her most recent appointment, Jyoti served as Chief Business Officer of Medsir where she built a global business team which comprises of multiple segments: Sales, Business Development, Marketing and PI outreach.
Prior to this Jyoti worked as a Director of Business Development at Sinclair Research and helped achieve hypergrowth leading to an acquisition by Altasciences. She also held similar roles at Champions Oncology and Covance to improve the productivity of drug development.
Jyoti says: “I am excited to bring my extensive business and scientific experience to help expand the customer base and to provide the opportunity for US clients to benefit from Cellomatics pre clinical expertise..”
Of Jyoti’s appointment, Shailendra said: “Her wealth of experience in executive leadership roles, deep understanding of the US market and its work culture will be an invaluable asset to Cellomatics. I am therefore delighted to welcome her to the team and look forward to working closely with her.”
Keep an eye on our news page to see the latest news and updates as we continue our US expansion and further development of Cellomatics.
